Signal: Lilly searches for new obesity drugs in partnership with Fauna Bio
The deal is worth up to $494m plus royalties and allows Lilly to utilise Fauna’s Convergence artificial intelligence platform.
The deal is worth up to $494m plus royalties and allows Lilly to utilise Fauna’s Convergence artificial intelligence platform.